AR-NTD
PCCTC and Jake Vinson
Preparing AR-NTD programs for clinical development through trial design, endpoint strategy, U.S. site, regulatory, and operational planning.
- Early clinical development planning
- Protocol and endpoint strategy
- U.S. site and operational readiness
Why we partner
Moving a preclinical prostate cancer program toward possible clinical development requires decisions about trial logic well before any study begins. We work with Jake Vinson and the Prostate Cancer Clinical Trials Consortium to pressure-test those assumptions for Peptone's AR-NTD antagonist program as it matures. This collaboration is preparatory planning and does not indicate regulatory authorization, site activation, enrollment, or an active clinical trial.
Clinical-development focus
PCCTC combines a prostate cancer clinical consortium with infrastructure for study design, regulatory oversight, clinical operations, data management, statistics, quality assurance, and correlative science. At this stage, the focus is design: potential patient populations, protocol structure, objectives and endpoints, biomarker and correlative strategy, and the evidence thresholds that would support a future decision to advance.
What Peptone brings
Peptone brings the target product profile, mechanism-of-action evidence, preclinical datasets, and development assumptions for its AR-NTD antagonist program. The program is at development candidate stage. Keeping those inputs program-specific allows clinical planning to inform future evidence packages without presenting any program as clinical stage.
What we plan together
Together, we are developing scenario-based trial concepts and reviewing protocol and endpoint choices for future AR-NTD candidates. The work also maps a potential U.S. site strategy and the regulatory, operational, data, quality, and vendor requirements that would need to be ready before a study could open. Planning remains contingent on candidate selection, preclinical evidence, and the applicable regulatory steps.
Future rollout
If an AR-NTD candidate later clears its preclinical and regulatory gates, this work can support a disciplined rollout across appropriate U.S. prostate cancer research sites, with expansion guided by the protocol, operational performance, and emerging evidence. PCCTC's network includes more than 200 academic and community research sites globally, providing a framework for future scale. Any rollout remains future and contingent; no active study or enrollment is represented here.